265 related articles for article (PubMed ID: 29033011)
1. Usefulness of positron emission tomography (PET)/contrast-enhanced computed tomography (CE-CT) in discriminating between malignant and benign intraductal papillary mucinous neoplasms (IPMNs).
Ohta K; Tanada M; Sugawara Y; Teramoto N; Iguchi H
Pancreatology; 2017; 17(6):911-919. PubMed ID: 29033011
[TBL] [Abstract][Full Text] [Related]
2. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules.
Takanami K; Hiraide T; Tsuda M; Nakamura Y; Kaneta T; Takase K; Fukuda H; Takahashi S
Ann Nucl Med; 2011 Aug; 25(7):501-10. PubMed ID: 21537945
[TBL] [Abstract][Full Text] [Related]
3. Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrast-enhanced endoscopic ultrasonography.
Harima H; Kaino S; Shinoda S; Kawano M; Suenaga S; Sakaida I
World J Gastroenterol; 2015 May; 21(20):6252-60. PubMed ID: 26034360
[TBL] [Abstract][Full Text] [Related]
4. Does PET with CT Have Clinical Utility in the Management of Patients with Intraductal Papillary Mucinous Neoplasm?
Roch AM; Barron MR; Tann M; Sandrasegar K; Hannaford KN; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
J Am Coll Surg; 2015 Jul; 221(1):48-56. PubMed ID: 26095551
[TBL] [Abstract][Full Text] [Related]
5. Use of F-18 fluorodeoxyglucose positron emission tomography with dual-phase imaging to identify intraductal papillary mucinous neoplasm.
Saito M; Ishihara T; Tada M; Tsuyuguchi T; Mikata R; Sakai Y; Tawada K; Sugiyama H; Kurosawa J; Otsuka M; Uchida Y; Uchiyama K; Miyazaki M; Yokosuka O
Clin Gastroenterol Hepatol; 2013 Feb; 11(2):181-6. PubMed ID: 23142206
[TBL] [Abstract][Full Text] [Related]
6. Comparison of International Consensus Guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas.
Pedrazzoli S; Sperti C; Pasquali C; Bissoli S; Chierichetti F
Ann Surg; 2011 Dec; 254(6):971-6. PubMed ID: 22076067
[TBL] [Abstract][Full Text] [Related]
7. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
8. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
[TBL] [Abstract][Full Text] [Related]
9. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.
Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR
JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085
[TBL] [Abstract][Full Text] [Related]
10. Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules.
Ohno E; Hirooka Y; Itoh A; Ishigami M; Katano Y; Ohmiya N; Niwa Y; Goto H
Ann Surg; 2009 Apr; 249(4):628-34. PubMed ID: 19300203
[TBL] [Abstract][Full Text] [Related]
11. Utility of whole-lesion ADC histogram metrics for assessing the malignant potential of pancreatic intraductal papillary mucinous neoplasms (IPMNs).
Hoffman DH; Ream JM; Hajdu CH; Rosenkrantz AB
Abdom Radiol (NY); 2017 Apr; 42(4):1222-1228. PubMed ID: 27900458
[TBL] [Abstract][Full Text] [Related]
12. Malignant transformation of branch duct-type intraductal papillary mucinous neoplasms of the pancreas based on contrast-enhanced endoscopic ultrasonography morphological changes: focus on malignant transformation of intraductal papillary mucinous neoplasm itself.
Ohno E; Itoh A; Kawashima H; Ishikawa T; Matsubara H; Itoh Y; Nakamura Y; Hiramatsu T; Nakamura M; Miyahara R; Ohmiya N; Ishigami M; Katano Y; Goto H; Hirooka Y
Pancreas; 2012 Aug; 41(6):855-62. PubMed ID: 22481289
[TBL] [Abstract][Full Text] [Related]
13. F18-FDG-PET/CT for evaluation of intraductal papillary mucinous neoplasms (IPMN): a review of the literature.
Bertagna F; Treglia G; Baiocchi GL; Giubbini R
Jpn J Radiol; 2013 Apr; 31(4):229-36. PubMed ID: 23315020
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance and imaging features for predicting the malignant potential of intraductal papillary mucinous neoplasm of the pancreas: a comparison of EUS, contrast-enhanced CT and MRI.
Choi SY; Kim JH; Yu MH; Eun HW; Lee HK; Han JK
Abdom Radiol (NY); 2017 May; 42(5):1449-1458. PubMed ID: 28144718
[TBL] [Abstract][Full Text] [Related]
15. Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: preliminary results.
Baiocchi GL; Portolani N; Bertagna F; Gheza F; Pizzocaro C; Giubbini R; Giulini SM
J Exp Clin Cancer Res; 2008 Jun; 27(1):10. PubMed ID: 18577196
[TBL] [Abstract][Full Text] [Related]
16. Correlation between CT patterns and pathological classification of intraductal papillary mucinous neoplasm.
Zhang J; Wang PJ; Yuan XD
Eur J Radiol; 2010 Jan; 73(1):96-101. PubMed ID: 19008065
[TBL] [Abstract][Full Text] [Related]
17. Implications of imaging criteria for the management and treatment of intraductal papillary mucinous neoplasms - benign versus malignant findings.
Walter TC; Steffen IG; Stelter LH; Maurer MH; Bahra M; Faber W; Klein F; Bläker H; Hamm B; Denecke T; Grieser C
Eur Radiol; 2015 May; 25(5):1329-38. PubMed ID: 25433414
[TBL] [Abstract][Full Text] [Related]
18. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases.
Nara S; Onaya H; Hiraoka N; Shimada K; Sano T; Sakamoto Y; Esaki M; Kosuge T
Pancreas; 2009 Jan; 38(1):8-16. PubMed ID: 18665010
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of diffusion restriction in intraductal papillary mucinous neoplasm of the pancreas in comparison with "high-risk stigmata" of the 2012 international consensus guidelines for prediction of the malignancy and invasiveness.
Kim M; Mi Jang K; Kim SH; Doo Song K; Jeong WK; Kang TW; Kim YK; Cha DI; Kim K; Yoo H
Acta Radiol; 2017 Oct; 58(10):1157-1166. PubMed ID: 28084815
[TBL] [Abstract][Full Text] [Related]
20. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
